Anktiva Immunotherapy Drug for Cancer
Here’s a summary table of cancer types where Anktiva (N‑803) is being tested or used:
| Cancer Type | Trial Phase / Status | Combination / Approach | Notes |
|---|---|---|---|
| Bladder (NMIBC) | FDA Approved (Phase 3 complete) | Intravesical with BCG | 62% CR rate; sustained responses up to 53+ months |
| Non-Hodgkin Lymphoma | Phase I (CARMEN-803) | Post-CAR T maintenance | Enhances CAR-T persistence |
| Non-Small Cell Lung | Phase Ib/II completed; Phase III starting | Nivolumab + N‑803; Tislelizumab + Docetaxel | Targeting ICI-resistant NSCLC |
| Neuroblastoma | Pediatric trial ongoing | Chemoimmunotherapy + N‑803 | Relapsed/refractory cases |
| Ovarian / Peritoneal | Phase II | Intraperitoneal or SC N‑803; chemo + NK therapy | Platinum-resistant disease |
| Pancreatic | Compassionate use; exploratory | N‑803 + NK cells + ADC | Case report: stable disease, transient CR |
| Broad Solid Tumors | Phase I (QUILT-3.076) | Memory-like NK cells + N‑803 | Advanced/metastatic tumors |
| Expanded Access | FDA-authorized program | N‑803 for lymphopenia in heavily pretreated patients | Early survival benefit signals |
No Comments
You must log on to comment.